Perimeter Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results Marked by Record Revenues and Improved Operating Performance Accessibility StatementSkip Navigation Conference Call/Webcast Today at 5:00 pm ET TORONTO and DALLAS, March 31, 2026 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, today reported preliminary unaudited financial results for its fourth quarter ...

Financial Data and Key Metrics Changes - The company reported total revenue of $16 million for Q4 2025, representing a 4% decline year-over-year, primarily due to lower system sales [18] - Full year 2025 revenue increased by 9% compared to 2024, with recurring revenue growing by 15% [20][21] - The gross margin for Q4 was 43%, slightly up from 42% in Q4 2024, while the full year gross margin was 46%, down from 48% in 2024 [22][23] Business Line Data and Key Metrics Changes - The installed base of ALLY systems grew to approximately 200, with a 48% year-over-year increase, and procedure volume increased by 20% year-over-year [22] - The company achieved a 23.4% procedure share in the U.S. by the end of 2025, up from 14% [10] - The company placed 15 ALLY systems in Q4 2025, contributing to a total of 206,000 procedures globally for the year [22] Market Data and Key Metrics Changes - U.S. ALLY sales increased by one system to 12 in Q4 2025, while international sales dropped significantly from 10 systems in Q4 2024 to just one in Q4 2025 [18][19] - The company noted that the uncertainty surrounding the acquisition negatively impacted international business expansion [13] Company Strategy and Development Direction - The company aims to focus on growing procedure volumes and recurring revenue through additional system placements and increased utilization of existing systems [15] - The strategy includes re-engaging with distributors and stakeholders to regain momentum lost during the acquisition process [14] - The company plans to explore new markets, including Australia and New Zealand, and expand its presence in Europe and Southeast Asia [50][55] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about returning to historical operating performance and emphasized the importance of rebuilding momentum over the next several quarters [9][61] - The company acknowledged the challenges faced during the acquisition process but highlighted the validation of its technology and market position [5][6] - Management expects to see gradual improvements in system sales and recurring revenue as distributors re-engage [20][42] Other Important Information - The company received a $10 million transaction deposit following the termination of the acquisition, which will enhance its cash position [8][17] - The company recorded $17.1 million in total acquisition costs in 2025, with a portion expected to be eliminated due to the termination of the merger [17] Q&A Session Summary Question: Can you elaborate on the distributor commentary and its impact on growth? - Management indicated that while conversations with distributors have been positive, it will take time to regain momentum in international markets due to previous uncertainties [29][32] Question: How should we think about the mix of capital placements versus lease-based placements? - Management noted that revenue recognition differs between U.S. and international sales, with a potential shift towards more lease-based placements in the U.S. [33][36] Question: Can you clarify the expected increase in operating expenses for 2026? - Management confirmed that cash-based operating expenses are expected to increase by 10%, excluding merger-related costs [37][38] Question: What is the outlook for U.S. procedure growth given recent trends? - Management reported that recurring revenue is becoming healthy, with expectations for continued growth in procedure volumes driven by the installed base [41][42] Question: Are there new market opportunities outside the U.S.? - Management expressed interest in exploring markets like Australia and New Zealand, as well as expanding in Europe and Southeast Asia [50][55]

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, and an equity method investment of INNOVATE, announced receipt of European Union (EU) CE Mark certification under the EU Medical Device Regulation (MDR) for its TGFR™ Monitor and TGFR™ Reusable Sensor. The certification confirms that ...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, March 31, 2026 (GLOBE NEWSWIRE) -- Vitalist Inc. (TSX-V: VITA.V) ("Vitalist"), a wearable operating-system focused technology company, today announced that it has entered into a definitive merger agreement dated March 30, 2026 (the "Merger Agreement") to acquire 100% of the issued and outstanding equity securities of Somatix, Inc. ("Somatix"), a New York-based medical technology company focuse ...

Photo by Kost9n4 on Pixabay Boston Scientific (BSX) has lost a third of its value year-to-date, including a single-session drop of 9% on March 30. For a company with a multi-year track record of double-digit revenue growth, that's a significant drawdown. Is this a buying opportunity, or is the market correctly repricing a structurally weaker growth story? We unpack this below. Why Did BSX Fall Yesterday? The immediate trigger was CHAMPION-AF trial data for the Watchman FLX device. The trial met its end ...

Core Insights - ONWARD Medical N.V. reported significant advancements in its neurotechnology products, particularly the ARC-EX System, which aims to restore movement and function in individuals with spinal cord injuries (SCI) and other movement disabilities [1][25]. Commercial Traction - The company established a US commercial organization, leading to the sale of 117 ARC-EX Systems in 2025, with over 80 US clinics adopting the technology, achieving a market penetration of approximately 25% in specialized rehabilitation clinics [3][5]. - The ARC-EX System received FDA 510(k) clearance for home use, expanding market opportunities and enhancing access for the SCI community [2][6]. Regulatory Milestones - The company achieved CE Mark certification for the ARC-EX System, allowing commercialization in the EU for both clinic and home use [5][6]. - The FDA approved an investigational device exemption (IDE) for the ARC-IM System, enabling the initiation of the Empower BP global pivotal study to assess its effectiveness in managing blood pressure instability in SCI patients [7][9]. Science & Technology Leadership - Positive results from the Pathfinder2 study indicated significant functional improvements in patients using ARC-EX Therapy, with continued gains in upper body strength and balance [8]. - The company published two landmark articles in Nature and Nature Medicine, supporting the clinical evidence for the ARC-IM System and its potential benefits for blood pressure regulation after SCI [9]. Financial Results - The company reported total revenue of EUR 5.4 million for 2025, with revenue from ARC-EX System sales increasing from EUR 0.08 million in 2024 to EUR 3.7 million in 2025 [15][17]. - Operating loss for the period was EUR 40.9 million, reflecting increased investments in commercialization and infrastructure [16][17]. Corporate Governance - The company appointed Professor Tim Denison and Lucas Buchanan to its Board of Directors, enhancing its leadership in neurotechnology [13]. - In January 2026, Ali Kiboro was appointed as Chief Financial Officer, bringing experience from a NASDAQ-listed company [14]. Outlook - The company anticipates strong commercial results in 2026, driven by new regulatory approvals and demand for the ARC-EX System, along with plans for the Empower BP study and further advancements in its therapy pipeline [21][22].

Financial Data and Key Metrics Changes - For the full year 2025, RenovoRx generated over $1 million in revenue, with fourth quarter revenues at $238,000, reflecting initial adoption of RenovoCath [6][20] - Gross profit for Q4 was $210,000, resulting in a gross margin of 88% [21] - Research and development expenses for Q4 were $1.5 million, totaling $6.3 million for the year, indicating continued investment in clinical trials [21] - Selling, general, and administrative expenses for Q4 were $2.2 million, with a total of $7 million for the year, reflecting disciplined cost management [21] Business Line Data and Key Metrics Changes - The company exited Q4 with nine active commercial centers, with three becoming active in the last two weeks of the year [7] - As of February 27, 2026, 12 U.S. cancer centers are utilizing RenovoCath, with 21 additional centers evaluating the device, representing a tripling of the near-term pipeline compared to Q1 2025 [9] Market Data and Key Metrics Changes - The company is targeting approximately 36 active commercial sites by year-end 2026, tripling the current footprint of 12 [10][24] - The growth in active commercial sites is expected to drive revenue growth, with a projected revenue range of $3 million to $4 million for 2026 [25] Company Strategy and Development Direction - RenovoRx is focused on scaling its commercial operations and expanding its network of active commercial cancer center clients [10][11] - The company aims to deepen utilization at existing sites while expanding its commercial footprint, supported by a robust pipeline of centers [10][11] - The transition of TIGeR-PaC trial centers to commercial customers is seen as a key strategy for growth [30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the commercial viability of RenovoCath, citing strong physician demand and ongoing clinical evidence supporting its effectiveness [10][15] - The company is optimistic about achieving significant revenue growth in 2026, driven by new site activations and increased orders [23][25] Other Important Information - The company closed an oversubscribed private placement on March 23, 2026, resulting in gross proceeds of approximately $10 million, providing financial flexibility for scaling operations [22] - The TIGeR-PaC trial is on track, with 104 patients randomized as of March 24, 2026, and final data anticipated in 2027 [16] Q&A Session Summary Question: Transitioning TIGeR-PaC centers to commercial customers - Management indicated that transitioning is simpler due to existing familiarity and training of physicians, with most centers already having pricing agreements in place [29] Question: Catheter outlook and revenue expectations - Management refrained from providing specific revenue guidance but expressed confidence in significant growth over Q4 based on early 2026 activity [33][35] Question: Active centers and revenue generation - Management clarified that 12 centers are currently active, with 21 more in the approval process, and emphasized the importance of converting trial centers to commercial use [41][51] Question: G&A expenses and future projections - Management expects G&A expenses to remain around $2.2 million per quarter, with slight increases as additional sales personnel are added [42][44]

NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Institutional investors holding positions in Boston Scientific Corporation (NYSE: BSX) during the period from July 23, 2025, through February 3, 2026, may wish to evaluate lead plaintiff opportunities in a pending securities class action. Request an institutional investor loss assessment. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or call (212) 363-7500. BSX shares fell from $91.62 to $75.50 on February 4, 2026, a single-day loss of $16. ...

Core Insights - Envista (NVST) shares have increased by 42.5% over the past year, significantly outperforming the industry's decline of 22.5% and the S&P 500's gain of 16.6% [1][9] - The company is recognized as a Zacks Rank 1 (Strong Buy), indicating strong potential for wealth creation for investors [1] Company Overview - Envista, headquartered in Brea, CA, has been built through the acquisition of over 25 leading dental businesses over 15 years, forming a global family of more than 30 dental brands [2] - The company operates through two segments: Specialty Products & Technologies and Equipment & Consumables, providing comprehensive solutions for dental treatments [2] Growth Drivers - The surge in Envista's share price is attributed to strategic acquisitions that enhance its portfolio and expand into new economic sectors [3] - In the first half of 2025, Envista completed two small acquisitions at favorable EBITDA multiples, supporting its organic growth initiatives [3] - Positive growth was reported across key businesses and geographies in Q4 2025, driven by a double-digit increase in R&D investment [4] Operational Efficiency - Envista has successfully reduced company-wide G&A expenses by 10% year over year while maintaining high standards of safety, quality, and customer service [4] - The company expanded its manufacturing footprint in China with a new site in Suzhou to meet growing local demand [5] Financial Health - Envista has a strong financial position with zero current debt and cash and cash equivalents of $1.21 billion at the end of 2025, providing flexibility amid macroeconomic uncertainty [6] - The net debt to adjusted EBITDA ratio stands at approximately 0.6X, indicating stability [6] Future Projections - Earnings per share (EPS) for 2026 and 2027 are expected to increase by 18.5% and 10.5%, reaching $1.41 and $1.55, respectively [11] - Revenues are projected to grow by 4.5% to $2.84 billion in 2026 and are expected to reach $2.95 billion in 2027, implying a 3.7% increase [11]

Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform Accessibility StatementSkip Navigation About AbbottAbbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries. ...